Nextcure reports first quarter 2021 financial results

Beltsville, md., may 06, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update.
NXTC Ratings Summary
NXTC Quant Ranking